Beyond telomerase enzymatic activity, TERT mRNA expression level has been studied as biomarker, because it has been demonstrated to be the rate-limiting determinant of telomerase activity in various malignancies, such as urothelial cancer [76], non-small cell lung cancer [77], and breast cancer [78]. This evidence concerns the gene TERT and breast cancer.